An Impartial Viewpoint Of Paclitaxel

2%; 95% confidence interval [CI], ?5.2, 2.8. As the criterion for declaring noninferiority was prespecified as the lower boundary of the 95% CI for the difference in 12-month rates of graft loss being not less than 5%, the study did not meet its primary safety end point of noninferiority in graft loss rates. All cumulative graft loss events in the SRL-conversion group and all but 1 in the CNI-continuation group (resulting in retransplantation) were attributable to death. Between-group differences in graft loss events through month 72 were not significant (Figure 4A). Cumulative data did not assign missing data as events; patients missing their last http://www.selleckchem.com/products/pirfenidone.html visit were censored at time of last follow-up. Differences in rates of death in the SRL-conversion and CNI-continuation groups in time-to-event analyses were not significant at 12 months (13 and 3, respectively) or cumulatively through 72 months (19 and 7, respectively). Most deaths occurred during the first 2 years. The BCAR rate at month 12 was significantly higher in the SRL-conversion group (p = 0.02) (Table 2). Any patient whose clinical rejection page was missing was scored as an ACR event. When excluding events for missing patients, rates were 6.4% http://www.selleckchem.com/products/Maraviroc.html versus 1.9% in the SRL and CNI groups, respectively. At 12 months, all moderate and most mild BCARs occurred in the SRL-conversion group. Cumulative BCAR rates through month 72 (Figure 4B) were numerically higher in the SRL group, but frequency was low and the difference was not significant. As with the cumulative graft loss/death analysis, patients with missing data were censored at time of last follow-up. Most BCARs in the SRL-conversion group (23/25) occurred early (within 3�C6 months). In the CNI-continuation group, 3/7 events occurred in the first 10 months. Cumulative treatment failure rates (defined as occurrence of ACR or premature discontinuation of assigned treatment) as of study end are shown in Figure 4C. Overall, treatment failure occurred in almost twice as many SRL-conversion patients as in CNI-continuation patients (48.3% and 26.7%, respectively; p http://www.selleck.cn/products/Paclitaxel(Taxol).html of dose discontinuation without acute rejection were 41.9% and 23.3%, respectively. Most treatment failures in the SRL-conversion cohort occurred in the first 12 months (126/188). In contrast, in the CNI-continuation cohort, 20/56 treatment failures occurred in the first 12 months. Table 3 shows the intent-to-treat analysis of the change in baseline-adjusted mean Cockcroft�CGault GFR at 12 months. Mean changes were not significantly different between groups. Nonparametric analysis by rank ANCOVA confirmed the absence of significant differences in adjusted GFRs between groups. Therefore, the study's primary efficacy objective was not met.